A Metabolic-Related Gene Signature for Predicting Biochemical Recurrence After Radical Prostatectomy: An Integrative Analysis and Targeted Therapeutic Validation
Open Access
- 26 May 2026
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (11) , 4797
Abstract
Biochemical recurrence (BCR) after radical prostatectomy (RP) remains a major clinical challenge. Although metabolic reprogramming drives prostate cancer (PCa) progression, its predictive value for BCR and its interplay with the tumor immune microenvironment (TIME) remain incompletely understood. By integrating weighted gene co-expression network analysis (WGCNA) with machine learning, we identified four metabolic-related hub genes (GDPD1, PLA2G7, PTGDS, and SRD5A2) and developed an XGBoost-Cox model that accurately stratified BCR risk (training 5-year AUC: 0.858; validation 5-year AUC: 0.745). SHAP analysis enhanced the model’s interpretability, while immunohistochemistry (IHC) validated differential protein expression of these targets across 32 clinical specimens. Furthermore, immune profiling demonstrated that these genes are closely linked to M2 macrophage-mediated immunosuppression and altered T-cell infiltration. To translate these biomarkers into therapeutic targets, we employed in silico screening, molecular docking, and molecular dynamics simulations, identifying (-)-epigallocatechin gallate (EGCG) as a promising multi-target candidate. Subsequent in vitro assays confirmed that EGCG binds stably to GDPD1, PTGDS, and SRD5A2, effectively suppressing malignant PCa phenotypes and prostate-specific antigen (PSA) secretion. In summary, we established a robust and interpretable model for predicting BCR after RP, and our in vitro validation suggests that EGCG holds promise as a therapeutic agent to delay PCa progression.Keywords
Funding Information
- Scientific Research Fund of the National Health and Wellness Commission - Major Science and Technology Plan Project for Health and Wellness in Zhejiang Province (WKJ-ZJ-2401)
This publication has 74 references indexed in Scilit:
- Epigallocatechin gallate circumvents drug‐induced resistance in non‐small‐cell lung cancer by modulating glucose metabolism and AMPK/AKT/MAPK axisPhytotherapy Research, 2023
- Subversion of infiltrating prostate macrophages to a mixed immunosuppressive tumor‐associated macrophage phenotypeClinical and Translational Medicine, 2022
- Lipogenic effects of androgen signaling in normal and malignant prostateAsian Journal of Urology, 2020
- Lipocalin‐type prostaglandin D synthase‐derived PGD2 attenuates malignant properties of tumor endothelial cellsThe Journal of Pathology, 2017
- Green tea catechin, epigallocatechin-3-gallate (EGCG): Mechanisms, perspectives and clinical applicationsBiochemical Pharmacology, 2011
- A gene signature identified using a mouse model of androgen receptor‐dependent prostate cancer predicts biochemical relapse in human diseaseInternational Journal of Cancer, 2011
- Promoter demethylation and chromatin remodeling by green tea polyphenols leads to re‐expression of GSTP1 in human prostate cancer cellsInternational Journal of Cancer, 2010
- Hepatotoxicity from green tea: a review of the literature and two unpublished casesEuropean Journal of Clinical Pharmacology, 2009
- Apoptotic effect of EGCG in HT-29 colon cancer cells via AMPK signal pathwayCancer Letters, 2007
- Epigallocatechin‐3‐gallate is a potent natural inhibitor of fatty acid synthase in intact cells and selectively induces apoptosis in prostate cancer cellsInternational Journal of Cancer, 2003